<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245803</url>
  </required_header>
  <id_info>
    <org_study_id>6998</org_study_id>
    <nct_id>NCT01245803</nct_id>
  </id_info>
  <brief_title>Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS</brief_title>
  <acronym>AVATAR</acronym>
  <official_title>Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <brief_summary>
    <textblock>
      Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>peri-procedural myocardial damage</measure>
    <time_frame>48 hours after PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>30 days after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Angioplasty</condition>
  <arm_group>
    <arm_group_label>rosuvastatin,one month,lipid lowering</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill, one month</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sugar pill is given 18-24hr and 4-6hr before PCI as control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>additional rosuvastatin loading</intervention_name>
    <description>additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI</description>
    <arm_group_label>rosuvastatin,one month,lipid lowering</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo control</intervention_name>
    <description>sugar pill is given 18-24hr and 4-6hr before PCI as control</description>
    <arm_group_label>sugar pill, one month</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 year old

          -  diagnosed as acute coronary syndrome

          -  Plan to PCI

        Exclusion Criteria:

          -  STEMI patient

          -  emergency PCI(&lt;2h) for NSTE-ACS

          -  History of liver disease and myopathy (ALT/AST&gt;3 x upper limit of normal,CK&gt;5 x upper
             limit of normal)

          -  TG&gt;500mg/dl,CCr&lt;30ml/min

          -  inflammatory disease

          -  allergic to rosuvastatin

          -  nephrotic syndrome,hypothyroidism,systemic lupus erythematosus,myeloma,et.al.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shujjuan Cheng, MD, PhD</last_name>
    <phone>+861064456995</phone>
    <email>chengshujuan1@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiying Li, MD</last_name>
    <phone>+861064456541</phone>
    <email>yingying2000@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the 28th division, Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>November 22, 2010</last_update_submitted>
  <last_update_submitted_qc>November 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>HYan</name_title>
    <organization>BeijingAnzhen</organization>
  </responsible_party>
  <keyword>rosuvastatin</keyword>
  <keyword>angioplasty</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

